Evidence map›Paper›PMID 27815383›Full record

Trial reportThe Journal of infectious diseases2017

Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.

Emmanuel Feroldi, Mark Boaz, Sutee Yoksan, Kulkanya Chokephaibulkit, Usa Thisyakorn, Chitsanu Pancharoen, Céline Monfredo, Alain Bouckenooghe

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase II
In one paragraph

Trial report in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00621764 (A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00621764 phase2completednot on this map

A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

TypeinterventionalSponsorSanofi Pasteur, a Sanofi CompanyRan2008 to 2013Enrolled300ConditionsJapanese Encephalitis, Hepatitis AArmsJapanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Innate, T-, and B-Cell Responses in Acute Human Zika Patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Emmanuel FeroldiClinical Development, Sanofi Pasteur, Marcy l'Etoile, France.
Mark BoazGlobal Clinical Immunology, Sanofi Pasteur, Swiftwater, Pennsylvania.
Sutee YoksanCenter for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Thailand and Translational Research Unit, Chulabhorn Research Institute.
Kulkanya ChokephaibulkitDivision of Infectious Diseases, Siriraj Hospital, Bangkok.
Usa ThisyakornDepartment of Pediatrics, Chulalongkorn Hospital, Bangkok, Thailand.
Chitsanu PancharoenDepartment of Pediatrics, Chulalongkorn Hospital, Bangkok, Thailand.
Céline MonfredoClinical Development, Sanofi Pasteur, Marcy l'Etoile, France.
Alain BouckenoogheMedical Affairs and Clinical R&D, Sanofi Pasteur, Singapore.
King Chulalongkorn Memorial Hospital · THSanofi (France) · FRMahidol University · THSanofi (United States) · USSiriraj Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe live-attenuated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induces a protective response in children. A shift in circulating JE virus strains suggests that a genotype shift phenomenon may occur throughout Southeast Asia. We assessed the neutralization of wild-type (WT) JE virus isolates at distal time points after vaccination.

methodsWe analyzed serum samples from a subset of 47 children who had received a JE-CV booster after an inactivated JE vaccine primary immunization. We measured antibody titers (50% plaque reduction neutralization test) using a panel of WT JE strains at baseline, then after the booster at 28 days and 6 months in all subjects present at the time points and in a subset at year 5. Three additional recent isolates were tested at year 5.

resultsOf 47 subjects, 43 (91.5%) subjects had JE neutralizing antibody titers ≥10 (reciprocal serum dilution) against the homologous strain before JE-CV boost; all were seroprotected up to year 5 after the JE-CV boost. Baseline WT seroprotection ranged between 78.7% and 87.2%; all subjects were seroprotected against the 4 WT strains at 28 days and 6 months; year 5 seroprotection ranged between 95.7% and 97.9%. Similar rates of protection against 3 additional WT isolates were observed at year 5.

conclusionsThe long-term immune responses induced after a JE-CV booster dose in toddlers were able to neutralize WT viruses from various genotypes circulating in Southeast Asia and India. CLINICAL TRIALS REGISTRATION: NCT00621764.

Indexed as

Cross ReactionsAnimalsAntibodies, NeutralizingAntibodies, ViralAsia, SoutheasternChild, PreschoolEncephalitis Virus, JapaneseFemaleHumansIndiaJapanese Encephalitis VaccinesMaleTime FactorsAntibodies, NeutralizingAntibodies, ViralJapanese Encephalitis Vaccinescross-neutralizationgenotypesJapanese encephalitis vaccineslong-term protectionwild-type strains

Identifiers

PMID27815383
PMCPMC5439595
OpenAlexW2547515617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.